These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Metabolism and pharmacokinetics of natural immunomodulators]. Bocci V; Pacini A; Pessina GP; Maioli E Ann Ist Super Sanita; 1987; 23(4):761-3. PubMed ID: 2454597 [No Abstract] [Full Text] [Related]
3. Physicochemical and biologic properties of interferons and their potential uses in drug delivery systems. Bocci V Crit Rev Ther Drug Carrier Syst; 1992; 9(2):91-133. PubMed ID: 1378776 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of tumor necrosis factor alpha after intravenous administration in rats. Dose dependence and influence of tumor necrosis factor beta. Zahn G; Greischel A Arzneimittelforschung; 1989 Sep; 39(9):1180-2. PubMed ID: 2590273 [TBL] [Abstract][Full Text] [Related]
5. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649 [TBL] [Abstract][Full Text] [Related]
6. [Interleukins and TNF in septic shock]. Guidet B; Staikowsky F; Offenstadt G Rev Prat; 1993 Jan; 43(1):13-7. PubMed ID: 8469892 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775 [TBL] [Abstract][Full Text] [Related]
8. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Anderson PM; Sorenson MA Clin Pharmacokinet; 1994 Jul; 27(1):19-31. PubMed ID: 7955769 [TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers. Trinchard-Lugan I; Ho-Nguyen Q; Bilham WM; Buraglio M; Ythier A; Munafo A Eur Cytokine Netw; 2001; 12(3):391-8. PubMed ID: 11566619 [TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice. Kamada H; Tsutsumi Y; Yamamoto Y; Kihira T; Kaneda Y; Mu Y; Kodaira H; Tsunoda SI; Nakagawa S; Mayumi T Cancer Res; 2000 Nov; 60(22):6416-20. PubMed ID: 11103807 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice. Ferraiolo BL; Moore JA; Crase D; Gribling P; Wilking H; Baughman RA Drug Metab Dispos; 1988; 16(2):270-5. PubMed ID: 2898346 [TBL] [Abstract][Full Text] [Related]
12. Bioavailability of recombinant tumor necrosis factor determines its lethality in mice. Ameloot P; Takahashi N; Everaerdt B; Hostens J; Eugster HP; Fiers W; Brouckaert P Eur J Immunol; 2002 Oct; 32(10):2759-65. PubMed ID: 12355427 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of recombinant human tumor necrosis factor alpha in rhesus monkeys after intravenous administration. Greischel A; Zahn G J Pharmacol Exp Ther; 1989 Oct; 251(1):358-61. PubMed ID: 2795465 [TBL] [Abstract][Full Text] [Related]
14. Mediation of anorexia by human recombinant tumor necrosis factor through a peripheral action in the rat. Bodnar RJ; Pasternak GW; Mann PE; Paul D; Warren R; Donner DB Cancer Res; 1989 Nov; 49(22):6280-4. PubMed ID: 2804974 [TBL] [Abstract][Full Text] [Related]
15. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Xiang H; Nguyen CB; Kelley SK; Dybdal N; Escandón E Drug Metab Dispos; 2004 Nov; 32(11):1230-8. PubMed ID: 15282212 [TBL] [Abstract][Full Text] [Related]
16. [Radioprotective effect of a complex preparation of lymphokinin cytokines]. Boĭko VN; Shadrin OV; Derevianchenko IG; Buntsevich AM; Bykovskaia SN Biull Eksp Biol Med; 1994 Jul; 118(7):38-40. PubMed ID: 7919271 [No Abstract] [Full Text] [Related]
17. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation. Tsutsumi Y; Kihira T; Tsunoda S; Kamada H; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T J Pharmacol Exp Ther; 1996 Sep; 278(3):1006-11. PubMed ID: 8819479 [TBL] [Abstract][Full Text] [Related]
18. Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation. Thamm DH; Kurzman ID; Clark MA; Ehrhart EJ; Kraft SL; Gustafson DL; Vail DM Clin Cancer Res; 2010 Mar; 16(5):1498-508. PubMed ID: 20160058 [TBL] [Abstract][Full Text] [Related]
19. Drug interaction studies of therapeutic proteins or monoclonal antibodies. Mahmood I; Green MD J Clin Pharmacol; 2007 Dec; 47(12):1540-54. PubMed ID: 17962422 [TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor alpha and interleukin-1 stimulate bone resorption in vivo as measured by urinary [3H]tetracycline excretion from prelabeled mice. König A; Mühlbauer RC; Fleisch H J Bone Miner Res; 1988 Dec; 3(6):621-7. PubMed ID: 3266953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]